NASDAQ: CRME TSX: COM
VANCOUVER, May 16, 2017 /PRNewswire/ - Cardiome Pharma
Corp. (NASDAQ: CRME / TSX: COM) today announced a number of changes
to its senior management team. Commenting on the changes,
William Hunter, MD, CEO and
President of Cardiome, said "Cardiome is a very different company
than it was even a few years ago. We are no longer focused on a
single drug and are now a diversified Company selling multiple
medicines. We have built a fully integrated pharmaceutical company
that sells its products into almost every major pharmaceutical
market in the world outside of the United
States. We have licensed and acquired compelling medicines
and expect to add more products in the foreseeable future via our
robust business development pipeline. We feel that we are on the
cusp of significant operational momentum and our Team will evolve
as necessary in order to maximize the Company's potential."
Changes to the Management Team:
- Justin Renz joins Cardiome as
its new Chief Financial Officer (CFO),
- Jennifer Archibald, Cardiome's
current CFO, has been appointed to the position of Chief Business
Operations Officer,
- David Dean, Cardiome's VP
Business Development and Investor Relations, has been appointed to
the position of Chief Business Development Officer,
- Hugues Sachot, Cardiome's SVP Commercial, has been appointed to
the position of Chief Commercial Officer.
Commenting on the appointment of Mr. Renz as CFO, William Hunter, MD, CEO and President of
Cardiome said "We are thrilled to welcome such a talented and
energetic executive to our team. Justin's experience in fast-paced
environments and leading multiple activities across a diverse set
of business functions makes him an ideal fit for our
organization."
"I am extremely excited to join Cardiome's management team. I
view this as an exceptional opportunity to work alongside proven
industry leaders and to increase the profile of Cardiome amongst
industry peers as well as investors and analysts. I believe that
Cardiome's current operations will prove to be an outstanding
platform to build upon," said Justin
Renz.
Mr. Renz has extensive experience in the biopharmaceutical
industry. He most recently served as Executive Vice President,
Chief Financial Officer and Treasurer at Karyopharm Therapeutics,
which he joined in August 2014, where
he led core business and finance functions. Prior to Karyopharm,
Mr. Renz was Executive Vice President, Chief Financial Officer and
Treasurer at Zalicus Inc. (formerly CombinatoRx, Inc.), which he
joined in September 2006. He oversaw
multiple rounds of equity and debt financing and led the company's
asset monetization strategy and two reverse mergers. Prior to
Zalicus, Mr. Renz served in senior finance and accounting roles at
Serono, Inc. and Coley Pharmaceutical Group, Inc.
Earlier in his career, Mr. Renz held increasingly senior finance
positions at ArQule, Inc. and Millipore Corporation. Mr. Renz began
his career with Arthur Andersen LLP in 1993. He received a Bachelor
of Arts in Economics and Accounting from the College of the Holy Cross, a Master of Science in
Taxation from Northeastern University
and a Master of Business Administration from Suffolk University.
Commenting on the appointments of Ms. Jennifer Archibald, Mr. David Dean and Mr. Hugues Sachot, William
Hunter said "Cardiome's operations have grown significantly
and today's appointments reflect both Cardiome's, and these
executives' development. Jennifer has been critical to ensuring the
efficient financial operation of Cardiome's global business, which
crosses dozens of borders and operates in very complex
environments; her new role reflects those talents as she will be
responsible for driving operational excellence in the organization
globally beyond finance. David has proven himself key to many
aspects of Cardiome's business but today, Cardiome's future
potential is significantly greater as a result of the business
development pipeline currently under negotiation. It consists of
some of the most compelling acute care medicines the industry has
seen in years. With a recently bolstered balance sheet, we are
confident that we will announce exciting additions to our product
portfolio in the foreseeable future. Hugues has done a magnificent
job establishing and growing our commercial footprint, including
the recent addition of our Canadian sales force. The distribution
business that he put in place worldwide has grown to become a
material component of our revenues. I congratulate Jennifer, David
and Hugues on their achievements to date and look forward to their
continued contributions."
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company
dedicated to the development and commercialization of innovative
therapies that will improve the quality of life and health of
patients suffering from disease. Cardiome has two marketed,
in-hospital, cardiology products, BRINAVESS®
(vernakalant IV), approved in Europe, Canada, and other territories for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in
adults, and AGGRASTAT® (tirofiban HCl) a reversible GP
IIb/IIIa inhibitor indicated for use in patients with acute
coronary syndrome. Cardiome also commercializes
ESMOCARD® and ESMOCARD LYO® (esmolol
hydrochloride), a short-acting beta-blocker used to control rapid
heart rate in a number of cardiovascular indications, on behalf of
their partner Amomed in select European markets. Cardiome has also
licensed: XYDALBA™ (dalbavancin hydrochloride), a second
generation, semi-synthetic lipoglycopeptide approved in the EU for
the treatment of acute bacterial skin and skin structure infections
(ABSSSI) in adults for select European and Middle Eastern nations
and Canada from Allergan; and
TREVYENT®, a development stage drug device combination
that is under development for Pulmonary Arterial Hypertension for
Europe, the Middle East and for Canadian markets from
SteadyMed Therapeutics.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain
statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian
securities legislation that may not be based on historical fact,
including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Forward-
looking statements may involve, but are not limited to, comments
with respect to our objectives and priorities for 2016 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our
operations, research and development and product and drug
development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Many such known risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions in the United States,
Canada, Europe, and the other regions in which we
operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with,
governmental legislation and regulations; availability of financial
reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected
delays in pre-clinical and clinical product development processes;
adverse findings related to the safety and/or efficacy of our
products or products; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to expand
commercialization activities; and any other factors that may affect
our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by
the forward-looking statements in this presentation to differ
materially from our actual results. These operating risks include:
our ability to attract and retain qualified personnel; our ability
to successfully complete pre-clinical and clinical development of
our products; changes in our business strategy or development
plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to
finance our activities; and any other factors described in detail
in our filings with the Securities and Exchange Commission ("SEC")
available at www.sec.gov and the Canadian securities regulatory
authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in
their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current
expectations and we undertake no obligation to revise or update
such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.